BEIJING, Feb. 14, 2024 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the "Company"), a China-based insurance broker conducting business through its variable interest entity in China, today announced that TRX HongKong Investment Limited (“TRX HongKong”), a wholly-owned subsidiary of the Company, has entered into a sale and purchase agreement (the “SPA”) to acquire Peak Consulting Services Limited (the “Target") from Yuefu Company Limited (the “Vendor”), the sole shareholder of the Target. The Target is a licensed insurance brokerage in Hong Kong. This strategic acquisition represents a milestone in the Company's business to expand into the Hong Kong insurance brokerage market.
Pursuant to the SPA, the proposed acquisition (the “Acquisition”) is conditioned upon, among other things, the completion of a satisfactory diligence review of the Target by TRX HongKong prior to the consummation of the Acquisition.
The total consideration for the Acquisition is $1.5 million, to be paid in 3,472,222 of the Company’s Class A ordinary shares, which was calculated based on $0.432 per share, equivalent to 80% of the closing price of $0.54 per share on January 31, 2024, on NASDAQ.
Upon the consummation of the Acquisition, the management of TRX HongKong will work closely with the management of the Target to aim for a seamless integration of operations in an effort to deliver enhanced value propositions to insurance clients in the Hong Kong market.
Mr. Zhe Wang, Chairman and CEO of TIAN RUIXIANG Holdings Ltd, stated, "This acquisition aligns with our long-term strategic vision of establishing a presence beyond mainland China’s insurance brokerage market. We are excited about the growth opportunities in the Hong Kong market and are committed to leveraging our expertise and resources in order to capitalize on such opportunities."
About TIAN RUIXIANG Holdings Ltd
TIAN RUIXIANG Holdings Ltd, headquartered in Beijing, China, is an insurance broker operating in China through its China-based variable interest entity. It distributes a wide range of insurance products, which are categorized into two major groups: (1) property and casualty insurance, such as automobile insurance, commercial property insurance, liability insurance; and (2) other insurance, such as life insurance and health insurance. For more information, visit the company's website at http://ir.tianrx.com/.
Forward-Looking Statements
Recent TIRX News
- TIAN RUIXIANG Holdings Ltd Receives Notification of Non-compliance from Nasdaq Relating to Late Filing of Annual Report on Form 20-F • GlobeNewswire Inc. • 03/25/2024 08:30:00 PM
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 02/29/2024 09:28:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/14/2024 09:49:07 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:20:30 PM
- TIAN RUIXIANG Holdings Ltd’s Subsidiary Enters into Sale and Purchase Agreement for Licensed Insurance Broker in Hong Kong • GlobeNewswire Inc. • 02/14/2024 01:40:00 PM
- TIAN RUIXIANG Holdings Ltd Enters into Memorandum of Understanding to Acquire Licensed Insurance Broker in Hong Kong • GlobeNewswire Inc. • 01/08/2024 01:30:00 PM
- TIAN RUIXIANG Holdings Ltd Receives Nasdaq Notice of Deficiency Regarding Minimum Bid Price Requirement • GlobeNewswire Inc. • 12/05/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/30/2023 08:31:02 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 08/18/2023 08:31:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/27/2023 08:30:19 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/25/2023 08:31:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/28/2023 08:46:50 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM